ST-400 Investigational product
ST-400-01
Phase 2 gene_therapy completed
Quick answer
ST-400 Investigational product for Transfusion Dependent Beta-thalassemia is a Phase 2 program (gene_therapy) at SANGAMO THERAPEUTICS, INC with 1 ClinicalTrials.gov record(s).
Program details
- Company
- SANGAMO THERAPEUTICS, INC
- Indication
- Transfusion Dependent Beta-thalassemia
- Phase
- Phase 2
- Modality
- gene_therapy
- Status
- completed